Yilmaz et al. found significantly higher levels of MMP-2 in patients with NAFLD compared to healthy subjects, but these levels did not differentiate between simple steatosis and steatohepatitis [41], consistent with Ando et al.’s study, which also assessed MMP-2 as a potential marker for liver fibrosis progression [42]. The gene discussed is MMP2; the disease is metabolic dysfunction-associated steatotic liver disease.